^
    Back
    Association details:
    Biomarker:ERBB3 V659E
    Cancer:Non Small Cell Lung Cancer
    Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations

    Published date:
    06/01/2020
    Excerpt:
    One patient with V659E responded well to ERBB2 inhibitor lapatinib plus capecitabine as well as subsequent afatinib treatment upon progression.
    Secondary therapy:
    capecitabine
    DOI:
    10.1002/1878-0261.12733